Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.

MLA

Montagna, Michela, et al. “Relationship between Pharmacokinetic Profile of Subcutaneously Administered Alemtuzumab and Clinical Response in Patients with Chronic Lymphocytic Leukemia.” Haematologica, vol. 96, no. 6, June 2011, pp. 932–36. EBSCOhost, https://doi.org/10.3324/haematol.2010.033159.

APA

Montagna, M., Montillo, M., Avanzini, M. A., Tinelli, C., Tedeschi, A., Visai, L., Ricci, F., Vismara, E., Morra, E., & Regazzi, M. (2011). Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica, 96(6), 932–936. https://doi.org/10.3324/haematol.2010.033159

Chicago

Montagna, Michela, Marco Montillo, Maria A Avanzini, Carmine Tinelli, Alessandra Tedeschi, Livia Visai, Francesca Ricci, Eleonora Vismara, Enrica Morra, and Mario Regazzi. 2011. “Relationship between Pharmacokinetic Profile of Subcutaneously Administered Alemtuzumab and Clinical Response in Patients with Chronic Lymphocytic Leukemia.” Haematologica 96 (6): 932–36. doi:10.3324/haematol.2010.033159.